Immunocompromised and immunocompetent mouse models for head and neck squamous cell carcinoma

OncoTargets and Therapy

Volumn 9, Issue , 2016, Pages 545-555

  Lei, Zhen Ge ^a   Ren, Xiao Hua ^b   Wang, Sha Sha ^c   Liang, Xin Hua ^c   Tang, Ya Ling ^c  

^a NANCHANG UNIVERSITY   (China)

^b Sichuan Medical Science Academy and Sichuan Provincial People s Hospital   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

Head and neck squamous cell carcinoma; HNSCC; Immunocompetent models; Immunocompromised models; Mouse models; Transgenic models

Indexed keywords

ANIMAL MODEL; CANCER MODEL; EXPERIMENTAL MODEL; GENETIC ENGINEERING; GENETIC MODEL; HEAD AND NECK SQUAMOUS CELL CARCINOMA; IMMUNOCOMPETENCE; IMMUNOCOMPROMIZED PATIENT; MOUSE; MOUSE MODEL; NONHUMAN; REVIEW; SYNGENEICALLY TRANSPLANTED MODEL; TRANSGENIC MOUSE;

EID: 84957572220     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S95633     Document Type: Review

References (138)

1. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med. 2008;359(11):1143–1154
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300
3. Jung AC, Ray AM, Ramolu L, et al. Caveolin-1-negative head and neck squamous cell carcinoma primary tumors display increased epithelial to mesenchymal transition and prometastatic properties. Oncotarget. Epub October 12, 2015
4. Leemans RL, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011;11(1):9–22
5. Caligiuri I, Rizzolio F, Boffo S, et al. Critical choices for modeling breast cancer in transgenic mouse models. J Cell Physiol. 2012;227(8): 2988–2991
6. Herschkowitz JI, Lubet R. Mouse models of triple negative [basal-like/ claudin low] breast cancer. Breast Dis. 2010;32(1–2):63–71
7. Cheon DJ, Orsulic S. Mouse models of cancer. Annu Rev Pathol. 2011; 6:95–119
8. Smith LP, Thomas GR. Animal models for the study of squamous cell carcinoma of the upper aerodigestive tract: a historical perspective with review of their utility and limitations. Part A. Chemically-induced de novo cancer, syngeneic animal models of HNSCC, animal models of transplanted xenogeneic human tumors. Int J Cancer. 2006;118(9): 2111–2122
9. Lu SL, Herrington H, Wang XJ. Mouse models for human head and neck squamous cell carcinomas. Head Neck. 2006;28(10):945–954
10. Close DM, Xu T, Sayler GS, et al. In vivo bioluminescent imaging (BLI): noninvasive visualization and interrogation of biological processes in living animals. Sensors (Basel). 2011;11(1):180–206
11. Bissell MJ, Hines WC. Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med. 2011;17(3):320–329
12. Lorusso G, Ruegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol. 2008; 130(6):1091–1103
13. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454(7203):436–444
14. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–545
15. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100(1):57–70
16. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674
17. Flanagan SP. ‘Nude’, a new hairless gene with pleiotropic effects in the mouse. Genet Res. 1966;8(3):295–309
18. Pantelouris EM, Hair J. Thymus dysgenesis in nude (nu nu) mice. J Embryol Exp Morphol. 1970;24(3):615–623
19. Rygaard J, Povlsen CO. Heterotransplantation of a human malignant tumour to “Nude” mice. Acta Pathol Microbiol Scand. 1969;77(4): 758–760
20. Bosma GC, Custer RP, Bosma MJ. A severe combined immunodeficiency mutation in the mouse. Nature. 1983;301(5900):527–530
21. Prochazka M, Gaskins HR, Shultz LD, et al. The nonobese diabetic scid mouse: model for spontaneous thymomagenesis associated with immunodeficiency. Proc Natl Acad Sci U S A. 1992;89(8): 3290–3294
22. Shultz LD, Schweitzer PA, Christianson SW, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol. 1995;154(1):180–191
23. Povlsen CO, Rygaard J. Heterotransplantation of human epidermoid carcinomas to the mouse mutant nude. Acta Pathol Microbiol Scand A. 1972;80(6):713–717
24. Braakhuis BJ, Sneeuwloper G, Snow GB. The potential of the nude mouse xenograft model for the study of head and neck cancer. Arch Otorhinolaryngol. 1984;239(1):69–79
25. Yu FS, Yang JS, Yu CS, et al. Safrole induces apoptosis in human oral cancer HSC-3 cells. J Dent Res. 2011;90(2):168–174
26. Shen LC, Chen YK, Lin LM, et al. Anti-invasion and anti-tumor growth effect of doxycycline treatment for human oral squamous-cell carcinoma – in vitro and in vivo studies. Oral Oncol. 2010;46(3):178–184
27. Ito S, Ozawa S, Ikoma T, et al. Expression of a chemokine BRAK/ CXCL14 in oral floor carcinoma cells reduces the settlement rate of the cells and suppresses their proliferation in vivo. Biomed Res. 2010;31(3): 199–206
28. Liang X, Zhou H, Liu X, et al. Effect of local hyperthermia on lymphangiogenic factors VEGF-C and -D in a nude mouse xenograft model of tongue squamous cell carcinoma. Oral Oncol. 2010;46(2):111–115
29. Zhu GQ, Tang YL, Li L, et al. Hypoxia inducible factor 1α and hypoxia inducible factor 2α play distinct and functionally overlapping roles in oral squamous cell carcinoma. Clin Cancer Res. 2010;16(19): 4732–4741
30. Harada K, Itashiki Y, Takenawa T, et al. Effects of lentinan alone and in combination with fluoropyrimidine anticancer agent on growth of human oral squamous cell carcinoma in vitro and in vivo. Int J Oncol. 2010;37(3):623–631
31. Epperly MW, Lai SY, Kanai AJ, et al. Effectiveness of combined modality radiotherapy of orthotopic human squamous cell carcinomas in Nu/Nu mice using cetuximab, tirapazamine and MnSOD-plasmid liposome gene therapy. In Vivo. 2010;24(1):1–8
32. Ekshyyan O, Rong Y, Rong X, et al. Comparison of radiosensitizing effects of the mammalian target ofrapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma. Mol Cancer Ther. 2009;8(8):2255–2265
33. Dinesman A, Haughey B, Gates GA, et al. Development of a new in vivo model for head and neck cancer. Otolaryngol Head Neck Surg. 1990;103(5 Pt 1):766–774
34. Kawashiri S, Kumagai S, Kojima K, et al. Development of a new invasion and metastasis model of human oral squamous cell carcinomas. Eur J Cancer B Oral Oncol. 1995;31B(4):216–221
35. Kawashiri S, Kojima K, Kumagai S, et al. Effects of chemotherapy on invasion and metastasis of oral cavity cancer in mice. Head Neck. 2001;23(9):764–771
36. Kawashiri S, Noguchi N, Tanaka A, et al. Inhibitory effect of neoadjuvant chemotherapy on metastasis of oral squamous cell carcinoma in a mouse model. Oral Oncol. 2009;45(9):794–797
37. Umeda M, Yokoo S, Komori T, et al. Experimental model of invasion and metastasis by orthotopic transplantation of oral squamous and adenoid cystic carcinomas into the tongue of nude mice. Br J Oral Maxillofac Surg. 2001;39(5):376–380
38. Simon C, Nemechek AJ, Boyd D, et al. An orthotopic floor-of-mouth cancer model allows quantification of tumor invasion. Laryngoscope. 1998;108(11 Pt 1):1686–1691
39. Fang L, Wang H, Zhou L, et al. FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells. Toxicol Appl Pharmacol. 2011;251(1):8–15
40. Yadav A, Kumar B, Datta J, et al. IL-6 promotes head and neck tumor metastasis by inducing epithelial–mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res. 2011; 9(12):1658–1667
41. Shinriki S, Jono H, Ota K, et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin Cancer Res. 2009;15(17): 5426–5434
42. Jung HM, Phillips BL, Patel RS, et al. Keratinization-associated miR-7 and miR-21 regulate tumor suppressor reversion-inducing cysteinerich protein with kazal motifs (RECK) in oral cancer. J Biol Chem. 2012;287(35):29261–29272
43. Yang MH, Lin BR, Chang CH, et al. Connective tissue growth factor modulates oral squamous cell carcinoma invasion by activating a miR504/FOXP1 signalling. Oncogene. 2012;31(19):2401–2411
44. Lin YC, Chen HW, Kuo YC, et al. Therapeutic efficacy evaluation of curcumin on human oral squamous cell carcinoma xenograft using multimodalities of molecular imaging. Am J Chin Med. 2010; 38(2):343–358
45. Patel V, Marsh CA, Dorsam RT, et al. Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. Cancer Res. 2011;71(22):7103–7112
46. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest. 2010;120(1):41–50
47. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008; 8(10):755–768
48. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A. 2007;104(3): 973–978
49. Clay MR, Tabor M, Owen JH, et al. Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck. 2010;32(9):1195–1201
50. Sun S, Wang Z. Head neck squamous cell carcinoma c-Met cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis. Int J Cancer. 2011;129(10):2337–2348
51. Shrivastava S, Steele R, Sowadski M, et al. Identification of molecular signature of head and neck cancer stem-like cells. Sci Rep. 2015; 5:7819
52. Sharkey FE, Fogh J. Metastasis of human tumors in athymic nude mice. Int J Cancer. 1979;24(6):733–738
53. Johnson JI, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer. 2001;84(10):1424–1431
54. Macchiarini F, Manz MG, Palucka AK, et al. Humanized mice are we there yet? J Exp Med. 2005;202(10):1307–1311
55. Hiramatsu H, Nishikomori R, Heike T, et al. Complete of reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/ SCID/gammacnull mice model. Blood. 2003;102(3):873–880
56. Kambe N, Hiramatsu H, Shimonaka M, et al. Development of both human connective tissue-type and mucosal-type mast cells in mice from hematopoietic stem cells with identical distribution pattern to human body. Blood. 2004;103(3):860–867
57. Gardner DG. Spontaneous squamous cell carcinomas of the oral region in domestic animals: a review and consideration of their relevance to human research. Oral Dis. 1996;2(2):148–154
58. Levy BM, Gorlin R, Gottsegen R. A histologic study of the reaction of skin and mucous membrane to a single application of 9,10-dimethyl1,2-benzanthracene. J Dent Res. 1950;29:678–679
59. Nishioka H, Hishi K, Kyokane K. Human saliva inactivates mutagenicity of carcinogens. Mutat Res.1981;85:323–333
60. Salley JJ. Experimental carcinogenesis in the cheek pouch of the Syrian hamster. J Dent Res. 1954;33:253–262
61. Morris AL. Factors influencing experimental carcinogenesis in the hamster cheek pouch. J Dent Res. 1961;40:3–15
62. MacDonald DG. Comparison of epithelial dysplasia in hamster cheek pouch carcinogenesis and human oral mucosa. J Oral Pathol. 1981;10:186–191
63. Nauta JM, Roodenburg JL, Nikkels PG, et al. Comparison of epithelial dysplasia – the 4NQO rat palate model and human oral mucosa. Int J Oral Maxillofac Surg. 1995;24(1 Pt 1):53–58
64. Ciapparelli L, Retief DH, Fatti LP. The effect of zinc on 9,10-dimethyl1,2-benzanthracene (DMBA) induced salivary gland tumours in the albino rat – a preliminary study. S Afr J Med Sci. 1972;37(3): 85–90
65. Eveson JW. Animal models of intra-oral chemical carcinogenesis: a review. J Oral Pathol. 1981;10(3):129–146
66. Hawkins BL, Heniford BW, Ackermann DM, et al. 4NQO carcinogenesis: a mouse model of oral cavity squamous cell carcinoma. Head Neck. 1994;16(5):424–432
67. Tang XH, Knudsen B, Bemis D, et al. Oral cavity and esophageal carcinogenesis modeled in carcinogen-treated mice. Clin Cancer Res. 2004;10(1 Pt 1):301–313
68. Chang NW, Pei RJ, Tseng HC, et al. Co-treating with arecoline and 4-nitroquinoline 1-oxide to establish a mouse model mimicking oral tumorigenesis. Chem Biol Interact. 2010;183(1):231–237
69. Boyd NM, Reade PC. Temporal alterations in cytokeratin expression during experimental oral mucosal carcinogenesis. Carcinogenesis. 1991;12(10):1767–1771
70. Nauta JM, Roodenburg JL, Nikkels PG, et al. Epithelial dysplasia and squamous cell carcinoma of wistar rat palatal mucosa: 4NQO model. Head Neck. 1996;18(5):441–449
71. Vered M, Yarom N, Dayan D. 4NQO oral carcinogenesis: animal models, molecular markers and future expectations. Oral Oncol. 2005; 41(4):337–339
72. Liu X, He R, Chen W. A rat model of tongue mucosa squamous cell carcinoma induced by oral administration of 4NQO in drinking water. Zhonghua Kou Qiang Yi Xue Za Zhi. 1999;34(6):354–356
73. Rich AM, Reade PC. Epithelial–mesenchymal interactions in experimental oral mucosal carcinogenesis. J Oral Pathol Med. 2001;30(7): 389–397
74. Baba S, Yamada Y, Hatano Y, et al. Global DNA hypomethylation suppresses squamous carcinogenesis in the tongue and esophagus. Cancer Sci. 2009;100(7):1186–1191
75. Tang XH, Albert M, Scognamiglio T, et al. A DNA methyltransferase inhibitor and all-trans retinoic acid reduce oral cavity carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide. Cancer Prev Res (Phila). 2009;2(12):1100–1110
76. Hasina R, Martin LE, Kasza K, et al. ABT-510 is an effective chemopreventive agent in the mouse 4-nitroquinoline 1-oxide model of oral carcinogenesis. Cancer Prev Res (Phila). 2009;2(4):385–393
77. Chang NW, Tsai MH, Lin C, et al. Fenofibrate exhibits a high potential to suppress the formation of squamous cell carcinoma in an oral-specific 4-nitroquinoline 1-oxide/arecoline mouse model. Biochim Biophys Acta. 2011;1812(4):558–564
78. Zhou G, Hasina R, Wroblewski K, et al. Dual inhibition of vascular endothelial growth factor receptor and epidermal growth factor receptor is an effective chemopreventive strategy in the mouse 4-NQO model of oral carcinogenesis. Cancer Prev Res (Phila). 2010;3(11): 1493–1502
79. Sheu JJ, Hua CH, Wan L, et al. Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer Res. 2009;69(6): 2568–2576
80. Wong DY, Feinberg SE. Incidence of growth of syngeneic oral squamous cell carcinoma in C57B1 bg/bg beige mice. Zhonghua Yi Xue Za Zhi (Taipei). 1990;45(1):53–59
81. Fu KK, Rayner PA, Lam KN. Modification of the effects of continuous low dose rate irradiation by concurrent chemotherapy infusion. Int J Radiat Oncol Biol Phys. 1984;10(8):1473–1478
82. O’Malley BW Jr, Cope KA, Johnson CS, et al. A new immunocompetent murine model for oral cancer. Arch Otolaryngol Head Neck Surg. 1997;123(1):20–24
83. Hier MP, Black MJ, Shenouda G, et al. A murine model for the immunotherapy of head and neck squamous cell carcinoma. Laryngoscope. 1995;105(10):1077–1080
84. Thomas GR, Chen Z, Oechsli MN, et al. Decreased expression of CD80 is a marker for increased tumorigenicity in a new murine model of oral squamous-cell carcinoma. Int J Cancer. 1999;82(3):377–384
85. Thomas GR, Chen Z, Enamorado I, et al. IL-12- and IL-2-induced tumor regression in a new murine model of oral squamous-cell carcinoma is promoted by expression of the CD80 co-stimulatory molecule and interferon-gamma. Int J Cancer. 2000;86(3):368–374
86. Ahmed SU, Okamoto M, Oshikawa T, et al. Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of toll-like receptor 4. J Immunother. 2004;27(6):432–441
87. Cui N, Nomura T, Noma H, et al. Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice. Clin Cancer Res. 2005;11(7):2713–2719
88. Nomura T, Shibahara T, Katakura A, et al. Establishment of a murine model of bone invasion by oral squamous cell carcinoma. Oral Oncol. 2007;43(3):257–262
89. Lee JK, Lim SC, Kim HD, et al. KITENIN represents a more aggressive phenotype in a murine model of oral cavity squamous carcinoma. Otolaryngol Head Neck Surg. 2010;142(5):747–752
90. Furuta H, Osawa K, Shin M, et al. Selective inhibition of NF-κB suppresses bone invasion by oral squamous cell carcinoma in vivo. Int J Cancer. 2012;131(5):E625–E635
91. Myers JN, Holsinger FC, Jasser SA, et al. An orthotopic nude mouse model of oral tongue squamous cell carcinoma. Clin Cancer Res. 2002; 8(1):293–298
92. Zhang X, Liu Y, Gilcrease MZ, et al. A lymph node metastatic mouse model reveals alterations of metastasis-related gene expression in metastatic human oral carcinoma sublines selected from a poorly metastatic parental cell line. Cancer. 2002;95(8):1663–1672
93. Chen Z, Smith CW, Kiel D, et al. Metastatic variants derived following in vivo tumor progression of an in vitro transformed squamous cell carcinoma line acquire a differential growth advantage requiring tumor-host interaction. Clin Exp Metastasis. 1997;15(5):527–537
94. Stewart TA, Pattengale PK, Leder P. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell. 1984;38(3):627–637
95. Brinster RL, Chen HY, Messing A, et al. Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors. Cell. 1984;37(2):367–379
96. Sinn E, Muller W, Pattengale P, et al. Coexpression of MMTV/v-Haras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell. 1987;49(4):465–475
97. Adnane J, Jackson RJ, Nicosia SV, et al. Loss of p21WAF1/CIP1 accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model. Oncogene. 2000;19(47):5338–5347
98. Hundley JE, Koester SK, Troyer DA, et al. Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53. Mol Cell Biol. 1997;17(2):723–731
99. Barrington RE, Subler MA, Rands E, et al. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol Cell Biol. 1998;18(1):85–92
100. Bearss DJ, Subler MA, Hundley JE, et al. Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors. Oncogene. 2000;19(8):1114–1122
101. Petit T, Bearss DJ, Troyer DA, et al. p53-independent response to cisplatin and oxaliplatin in MMTV-ras mouse salivary tumors. Mol Cancer Ther. 2003;2(2):165–171
102. Schreiber K, Cannon RE, Karrison T, et al. Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors. Oncogene. 2004;23(22):3972–3979
103. Raimondi AR, Vitale-Cross L, Amornphimoltham P, et al. Rapid development of salivary gland carcinomas upon conditional expression of K-ras driven by the cytokeratin 5 promoter. Am J Pathol. 2006;168(5):1654–1665
104. Raimondi AR, Molinolo A, Gutkind JS. Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model. Cancer Res. 2009;69(10):4159–4166
105. Van der Weyden L, Alcolea MP, Jones PH, et al. Acute sensitivity of the oral mucosa to oncogenic K-ras. J Pathol. 2011;224(1):22–32
106. Caulin C, Nguyen T, Longley MA, et al. Inducible activation of oncogenic K-ras results in tumor formation in the oral cavity. Cancer Res. 2004;64(15):5054–5058
107. Miyamoto S, Yasui Y, Kim M, et al. A novel rasH2 mouse carcinogenesis model that is highly susceptible to 4-NQO-induced tongue and esophageal carcinogenesis is useful for preclinical chemoprevention studies. Carcinogenesis. 2008;29(2):418–426
108. Zhang Z, Wang Y, Yao R, et al. p53 Transgenic mice are highly susceptible to 4-nitroquinoline-1-oxide-induced oral cancer. Mol Cancer Res. 2006;4(6):401–410
109. Moral M, Segrelles C, Lara MF, et al. Akt activation synergizes with Trp53 loss in oral epithelium to produce a novel mouse model for head and neck squamous cell carcinoma. Cancer Res. 2009;69(3): 1099–1108
110. Ide F, Kitada M, Sakashita H, et al. p53 haploinsufficiency profoundly accelerates the onset of tongue tumors in mice lacking the xeroderma pigmentosum group A gene. Am J Pathol. 2003;163(5): 1729–1733
111. Brodie SG, Xu X, Li C, et al. Inactivation of p53 tumor suppressor gene acts synergistically with c-neu oncogene in salivary gland tumorigenesis. Oncogene. 2001;20(12):1445–1454
112. Park Y, Kim W, Lee JM, et al. Cytoplasmic DRAK1 overexpressed in head and neck cancers inhibits TGF-β1 tumor suppressor activity by binding to Smad3 to interrupt its complex formation with Smad4. Oncogene. 2015;34(39):5037–5045
113. Bragado P, Estrada Y, Parikh F, et al. TGF-β2 dictates disseminated tumour cell fate in target organs through TGF-β-RIII and p38α/β signalling. Nat Cell Biol. 2013;15(11):1351–1361
114. White RA, Malkoski SP, Wang XJ. TGFβ signaling in head and neck squamous cell carcinoma. Oncogene. 2010;29(40):5437–5446
115. Liu L, Tang XH, Scognamiglio T, et al. Oral carcinogenesis induced by 4-nitroquinoline 1-oxide in lecithin:retinol acyltransferase gene knockout mice. J Nutr Biochem. 2010;21(10):975–982
116. Cohen J, Chen Z, Lu SL, et al. Attenuated transforming growth factor beta signaling promotes nuclear factor-kappaB activation in head and neck cancer. Cancer Res. 2009;69(8):3415–3424
117. Bian Y, Hall B, Sun ZJ, et al. Loss of TGF-b signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation. Oncogene. 2012; 31(28):3322–3332
118. Sun ZJ, Zhang L, Hall B, et al. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model. Clin Cancer Res. 2012;18(19): 5304–5313
119. Sun ZJ, Zhang L, Zhang W, et al. Inhibition of mTOR reduces anal carcinogenesis in transgenic mouse model. PLoS One. 2013;8(10): e74888
120. Herzog A, Bian Y, Vander Broek R, et al. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wildtype TP53 in human xenograft and murine knockout models of head and neck cancer. Clin Cancer Res. 2013;19(14):3808–3819
121. Li Y, Li B, Xu B, et al. Expression of p53, p21(CIP1/WAF1) and eIF4E in the adjacent tissues of oral squamous cell carcinoma: establishing the molecular boundary and a cancer progression model. Int J Oral Sci. 2015;7:161–168
122. Jabbar S, Strati K, Shin MK, Pilot HC, Lambert PF. Human papillomavirus type 16 E6 and E7 oncoproteins act synergistically to cause head and neck cancer in mice. Virology. 2010;407(1):60–67
123. Griep AE, Herber R, Jeon S, et al. Tumorigenicity by human papillomavirus type 16 E6 and E7 in transgenic mice correlates with alterations in epithelial cell growth and differentiation. J Virol. 1993; 67(3):1373–1384
124. Herber R, Liem A, Pitot H, et al. Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene. J Virol. 1996;70(3):1873–1881
125. Song S, Gulliver GA, Lambert PF. Human papillomavirus type 16 E6 and E7 oncogenes abrogate radiation-induced DNA damage responses in vivo through p53-dependent and p53-independent pathways. Proc Natl Acad Sci U S A. 1998;95(5):2290–2295
126. Nguyen ML, Nguyen MM, Lee D, et al. The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6’s induction of epithelial hyperplasia in vivo. J Virol. 2003;77(12):6957–6964
127. Arbeit JM, Münger K, Howley PM, et al. Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J Virol. 1994;68(7):4358–4368
128. Ghim S, Jenson AB, Bubier JA, et al. Cataracts in transgenic mice caused by a human papillomavirus type 18 E7 oncogene driven by KRT1-14. Exp Mol Pathol. 2008;85(2):77–82
129. Song S, Pitot HC, Lambert PF. The human papillomavirus type 16 E6 gene alone is sufficient to induce carcinomas in transgenic animals. J Virol. 1999;73(7):5887–5893
130. Song S, Liem A, Miller JA, et al. Human papillomavirus types 16 E6 and E7 contribute differently to carcinogenesis. Virology. 2000; 267(2):141–150
131. Fong LY, Jiang Y, Riley M, et al. Prevention of upper aerodigestive tract cancer in zinc-deficient rodents: inefficacy of genetic or pharmacological disruption of COX-2. Int J Cancer. 2008;122(5): 978–989
132. Korpi JT, Kervinen V, Mäklin H, et al. Collagenase-2 (matrix metalloproteinase-8) plays a protective role in tongue cancer. Br J Cancer. 2008;98(4):766–775
133. Ide F, Oda H, Nakatsuru Y, et al. Xeroderma pigmentosum group A gene action as a protection factor against 4-nitroquinoline 1-oxide-induced tongue carcinogenesis. Carcinogenesis. 2001;22(4):567–572
134. Opitz OG, Quante M, von Werder A, et al. A mouse model of oralesophageal carcinogenesis. Onkologie. 2005;28(1):44–48
135. Declercq J, Van Dyck F, Van Damme B, et al. Upregulation of Igf and Wnt signalling associated genes in pleomorphic adenomas of the salivary glands in PLAG1 transgenic mice. Int J Oncol. 2008;32(5): 1041–1047
136. Andl T, Le Bras GF, Richards NF, et al. Concerted loss of TGFβmediated proliferation control and E-cadherin disrupts epithelial homeostasis and causes oral squamous cell carcinoma. Carcinogenesis. 2014;35(11):2602–2610
137. Opitz OG, Harada H, Suliman Y, et al. A mouse model of human oral-esophageal cancer. J Clin Invest. 2002;110(6):761–769
138. Stairs DB, Bayne LJ, Rhoades B, et al. Deletion of p120-catenin results in a tumor microenvironment with inflammation and cancer that establishes it as a tumor suppressor gene. Cancer Cell. 2011; 19(4):470–483.